Introduction

Diabetic ketoacidosis is defined by hyperglycemia, elevated ketones, and metabolic acidosis. The 2024 multi-society consensus from ADA, EASD, JBDS, AACE, and DTS stages DKA severity by acidosis: mild, moderate, and severe.1

Sodium bicarbonate has been used historically to correct severe metabolic acidosis in DKA. The biological rationale is intuitive: raise pH, improve cardiac contractility and vasopressor responsiveness, and blunt hyperkalemia. The problem is that decades of clinical evidence have not shown meaningful clinical benefit, while several harms are predictable.

Key Points

  • The 2024 consensus states that routine bicarbonate administration is not recommended.1
  • Even in severe DKA, the language is permissive: bicarbonate may be considered when pH is below 7.0, not automatically given.
  • Adult RCT and cohort evidence shows no improvement in glucose decline, ketone clearance, time to acidosis resolution, length of stay, or mortality.2-7
  • Harms include hypokalemia, paradoxical CSF acidosis, hypernatremia, decreased tissue oxygen unloading, and pediatric cerebral edema risk.

Pharmacology of Sodium Bicarbonate

Parameter Details
Mechanism Sodium bicarbonate dissociates into sodium and bicarbonate. Bicarbonate buffers excess hydrogen ions and raises serum pH. Generated CO2 crosses the blood-brain barrier faster than bicarbonate, creating concern for transient paradoxical CSF acidosis.
Dose Only consider if pH <7.0: 100 mmol sodium bicarbonate diluted in 400 mL sterile water and infused over 2 hours. Reassess arterial pH after each dose. Repeat every 2 hours until pH is above 7.0, then stop.1
Administration Infuse over 2 hours through a dedicated line. Do not push undiluted 8.4% sodium bicarbonate for DKA. Co-infuse potassium replacement when appropriate and monitor potassium every 1-2 hours.
Adverse Effects
Hypokalemia Paradoxical CSF acidosis Pediatric cerebral edema signal Hypernatremia Volume overload Decreased tissue oxygen unloading
Compatibility Avoid Y-site administration with regular insulin, calcium-containing solutions, catecholamines, ciprofloxacin, midazolam, vancomycin, dobutamine, or norepinephrine. Use a dedicated line when possible.

Clinical Pearl

Persistent acidosis usually means inadequate DKA treatment, not a bicarbonate deficit. Review insulin delivery, fluid strategy, potassium status, and missed precipitants before reaching for bicarbonate.

Overview of Key Evidence

Author / Year Design Comparison Key Findings
Morris, 19862 RCT
n=21 adults		 Variable-dose bicarbonate vs no bicarbonate in severe DKA No recovery benefit

No difference in glucose or ketone decline, or time to pH 7.30 / bicarbonate at least 15 mEq/L.
Gamba, 19913 Double-blind RCT
n=20 adults		 Bicarbonate vs saline placebo; both groups received standard insulin and fluids Transient pH bump only

pH improved at 2 hours, but no clinical or metabolic difference persisted beyond that window.
Viallon, 19994 Retrospective cohort
n=39 adults		 Bicarbonate vs no bicarbonate in severe DKA More potassium required

No normalization-time benefit; bicarbonate group required about twice as much potassium.
Latif, 20025 Editorial / analysis Review of alkali therapy data in severe DKA No demonstrated benefit

Suggested future trials should be limited to pH below 6.9 with hemodynamic compromise.
Chua, 20116 Systematic review
44 included articles		 Adult and pediatric DKA bicarbonate literature Evidence does not justify routine use

Transient pH improvement only; pediatric cerebral edema and potassium supplementation signals noted.
Duhon, 20137 Retrospective cohort
n=86 adults		 IV bicarbonate vs no bicarbonate in pH below 7.0 No time benefit

No difference in acidosis resolution or discharge; bicarbonate group required more insulin and more fluid in the first 24 hours.

When Should Bicarbonate Be Considered?

Do not use routinely

pH at or above 7.0, uncomplicated DKA, pediatric DKA outside cardiac arrest protocols, or as a reflex response to an anion gap.

Rare adult consideration

Arterial pH below 7.0 plus hemodynamic instability or refractory hyperkalemia despite standard DKA therapy.

What to do first

Confirm insulin delivery, fluids, potassium plan, ventilation, and missed precipitants such as sepsis, MI, pancreatitis, or SGLT2 inhibitor exposure.

If you give it

Use 100 mmol sodium bicarbonate in 400 mL sterile water over 2 hours, replace potassium aggressively, monitor potassium and pH closely, and stop once pH is above 7.0.

Clinical Conclusions

Routine sodium bicarbonate administration in DKA is not recommended. This is consistent with the 2024 multi-society consensus, the 2009 ADA statement, and JBDS inpatient guidance.1,8,10

The adult evidence shows at most a transient 2-hour pH improvement, without durable improvement in clinically important outcomes.

Bicarbonate can worsen the practical problems pharmacists are already managing in DKA: potassium shifts, sodium load, fluid burden, and line compatibility.

Reserve bicarbonate for rare adult cases with pH below 7.0 plus hemodynamic instability or refractory hyperkalemia. Do not use it as a substitute for insulin, fluids, potassium, and source control.

Full Reference List

  1. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257-1275 / Diabetologia. 2024;67:1455-1479. doi:10.1007/s00125-024-06183-8.
  2. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med. 1986;105(6):836-840. doi:10.7326/0003-4819-105-6-836. PMID: 3096181.
  3. Gamba G, Oseguera J, Castrejon M, Gomez-Perez FJ. Bicarbonate therapy in severe diabetic ketoacidosis: a double-blind, randomized, placebo-controlled trial. Rev Invest Clin. 1991;43(3):234-238. PMID: 1667955.
  4. Viallon A, Zeni F, Lafond P, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med. 1999;27(12):2690-2693. doi:10.1097/00003246-199912000-00014. PMID: 10628611.
  5. Latif KA, Freire AX, Kitabchi AE, Umpierrez GE, Qureshi N. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care. 2002;25(11):2113-2114. doi:10.2337/diacare.25.11.2113. PMID: 12401775.
  6. Chua HR, Schneider A, Bellomo R. Bicarbonate in diabetic ketoacidosis - a systematic review. Ann Intensive Care. 2011;1:23. doi:10.1186/2110-5820-1-23. PMID: 21906367.
  7. Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013;47(7-8):970-975. doi:10.1345/aph.1S014. PMID: 23737516.
  8. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. doi:10.2337/dc09-9032.
  9. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6:40. doi:10.1038/s41572-020-0165-1.
  10. Joint British Diabetes Societies Inpatient Care Group. The management of diabetic ketoacidosis in adults. Revised 2023.
Tags: DKA Sodium Bicarbonate Emergency Medicine Critical Care Pharmacy Friday Pearls